SCHEMBL17186735

SCHEMBL17186735

CCN(C(=O)C(C)(C)Oc1ccc(N)cc1F)c1ccc(Cl)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ HTR3A P46098 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ GCK P35557 1/20 0.34
▸ RORC P51449 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ PPARA Q07869 3/20 0.31
▸ FBP1 P09467 2/20 0.31
▸ PPARG P37231 2/20 0.31
▸ PPARD Q03181 2/20 0.31
▸ NR1H4 Q96RI1 2/20 0.31
▸ TSHR P16473 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17187011 0.87 PPARA (0.36) CHRM2CHRM3MAOAHTR2CCHRNA4
SCHEMBL17187100 0.84 ALDH1A1 (0.42) CYP3A4HSD11B1FBP1KDM4EALDH1A1
SCHEMBL17186887 0.82 GCK (0.38) GCKFBP1KDM4E
SCHEMBL17186940 0.75 RORC (0.62) RORC
SCHEMBL17186770 0.70 HSPB1 (0.47) GCKFBP1KDM4EALDH1A1HTT
SCHEMBL17186822 0.70 PPARA (0.50) HTR2CKCNH2CYP3A4PPARAPPARG
SCHEMBL798625 0.69 TSHR (0.49) RORCCYP3A4TSHRALDH1A1HTT
SCHEMBL27530767 0.67 PDE2A (0.41) KCNH2CYP3A4TSHRKDM4EALDH1A1
SCHEMBL15003278 0.66 CYP3A4 (0.47) RORCCYP3A4ALDH1A1
SCHEMBL28626726 0.65 NR1H2 (0.39) CYP3A4HSD11B1NR1H4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718817-B2 Aryl and heteroaryl ether compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-01 — — US disclosed
US-9718817-B2 Aryl and heteroaryl ether compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-01 — — US disclosed
US-9718817-B2 Aryl and heteroaryl ether compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-01 — — US disclosed
EP-3131880-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2017-02-22 — — EP disclosed
US-20170022195-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-01-26 — — US disclosed
US-20170022195-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-01-26 — — US disclosed
US-20170022195-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-01-26 — — US disclosed
CN-106232582-A Aryl and heteroaryl ether compound as ROR gamma modulators 格兰马克药品股份有限公司 2016-12-14 — — CN disclosed
WO-2015159233-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-10-22 — — WO disclosed
WO-2015159233-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2015-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022195-A1 ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC CHRM2 315/4885CHRM3 193/4885MAOA 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback